

PRIOR AUTHORIZATION REQUEST FORM

EVRYSDI™

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Evrysdi™ (risdiplam)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the therapy prescribed by, or in consultation with, a neurologist?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a confirmed diagnosis of spinal muscular atrophy (SMA) by molecular genetic testing of 5q SMA with one of the following: <ul style="list-style-type: none"> • 5q SMA homozygous gene deletion • 5q SMA homozygous gene mutation • Compound heterozygote mutation (e.g. deletion of SMN1 exon 7 and mutation of SMN1)? 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Does documentation show the member has SMA-associated signs and symptoms consistent with SMA types 1, 2, or 3?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does genetic testing confirm 2 copies of SMN2?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Is the member ≥ 2 months of age and ≤ 25 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	
6. Is the member dependent on any of the following: <ul style="list-style-type: none"> • Invasive ventilation or tracheostomy • Non-invasive ventilation support beyond naps and nighttime sleep? 	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Does the provider attest the member is not currently pregnant and has been counseled to use effective contraception during treatment and until 1 month after the last Evrysdi™ dose?	<input type="checkbox"/>	<input type="checkbox"/>	
8. Does the member have hepatic dysfunction?	<input type="checkbox"/>	<input type="checkbox"/>	

9. Has the member received Zolgensma®?	<input type="checkbox"/>	<input type="checkbox"/>	
10. Is the member currently taking Spinraza® or plans to take Evrysdi™ concurrently with Spinraza®?	<input type="checkbox"/>	<input type="checkbox"/>	
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member responded to initial therapy as shown by maintenance, improvement, or decreased decline in motor function?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM-117
 Origination Date: 10/01/2020
 Reviewed/Revised Date: 02/14/2022
 Next Review Date: 02/14/2023
 Current Effective Date: 03/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.